Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

NDORMS announces the closure of the Kennedy and Botnar Institutes and outlines other plans and activities for the department during the pandemic.

Coronavirus close up © Shutterstock

Regretfully, we are announcing the closure of the Kennedy and Botnar Institutes effective from noon on Wednesday 25 March. The Kadoorie Centre based at the John Radcliffe Hospital will remain open for staff working in clinical roles in the NHS and for essential follow-up of patients already recruited into clinical studies.

Many of our staff and postgraduate students will be continuing their day-to-day work from home, while others may take on or extend a clinical role to support the NHS in the fight against COVID-19. Some of our research teams are working towards solutions to contain the spread of coronavirus and we will share updates on this as we have them.

All new clinical research will be put on hold and recruitment of new participants to our clinical studies in Oxford will be paused.

For students, teaching and learning in Trinity term will be moved to an online format where possible, and there will be no conventional written paper exams. Detailed planning continues but our aim throughout is to ensure students can continue, or complete, their academic careers at Oxford. Most of our scheduled workshops/modules for postgraduate research students have been postponed and students are being advised to keep in touch with their supervisors.

Professor Andrew Carr, Head of Department said: "Researchers at NDORMS and across Oxford are at the forefront of global efforts to understand this coronavirus (COVID-19) and protect our communities.

I would like to thank all our teams at NDORMS who are supporting these efforts and the very responsible and collegiate way in which you have responded to this unprecedented situation. It is very stressful and disruptive for everyone particularly those with extra risk factors. In addition, many members of the department have family members and loved ones who are at high risk and many live in other countries where restrictions to travel make visits impossible."

The University of Oxford COVID-19 research hub features regular updates about the latest research publications and longer-form pieces covering the many ways Oxford is approaching this pandemic: www.ox.ac.uk/coronavirus-research.

Funding for Oxford's COVID-19 research requires unprecedented speed, scope and ambition and anyone wishing to fund the university's efforts can donate here: http://www.ox.ac.uk/coronavirus-research/support

For more information please contact communications@ndorms.ox.ac.uk in the first instance, and we can direct your enquiry to the appropriate team.

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.